Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — April 2021

Planlagt Fastgjort Låst Flyttet Genmab
1.3k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #135

    and from that - Genmab could spin out autoimmune disease unit, says CEO https://pharmaphorum.com/news/genmab-could-spin-out-autoimmune-disease-unit-says-ceo-goes-with-feature/

    1 Reply Last reply
    0
    • SolsenS Offline
      SolsenS Offline
      Solsen
      wrote on sidst redigeret af
      #136

      Det lyder spændende.

      1 Reply Last reply
      0
      • JørgenVarnæsJ Offline
        JørgenVarnæsJ Offline
        JørgenVarnæs
        wrote on sidst redigeret af
        #137

        Exciting stuff EL - good to hear there are no plans to build an “autoimmune” organization

        1 Reply Last reply
        0
        • JørgenVarnæsJ Offline
          JørgenVarnæsJ Offline
          JørgenVarnæs
          wrote on sidst redigeret af
          #138

          ...and about the merger stuff - that is just a lot of words until it is not. That is all about the number of zeros on the cheque...

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #139

            😉

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #140

              Link Preview Image
              Genmab-middel bliver bredere tilgængeligt i USA

              Tepezza, et Genmab-udviklet middel under ejerskab hos Horizon Therapeutics, er nu kommet ind i porteføljen af produkter udbudt gennem USA's største uafhængige specialapoteker.

              favicon

              (medwatch.dk)

              1 Reply Last reply
              0
              • royalR Offline
                royalR Offline
                royal
                wrote on sidst redigeret af
                #141

                Det lyder lidt som en salgstale fra Jan. (Som fanden læser biblen 🙂 )

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #142

                  Konkurrent til tiso

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #143

                    Link Preview Image
                    Exelixis' (EXEL) IND for Oncology Candidate Accepted by FDA

                    The FDA accepts Exelixis' (EXEL) IND for XB002 in patients with advanced solid tumors and a phase I study is expected to start in the second quarter.

                    favicon

                    Yahoo Finance (finance.yahoo.com)

                    1 Reply Last reply
                    0
                    • G Offline
                      G Offline
                      gdn55
                      wrote on sidst redigeret af
                      #144

                      Den samler vel bare kræfter. God købs mulighed her omkring, vil jeg mene.

                      1 Reply Last reply
                      0
                      • nohopeN Offline
                        nohopeN Offline
                        nohope
                        wrote on sidst redigeret af
                        #145

                        Iøvrigt mener jeg, at lukkeauktioner er svindel og bør stoppes.

                        1 Reply Last reply
                        0
                        • K Offline
                          K Offline
                          Klarussen
                          wrote on sidst redigeret af
                          #146

                          @pensionisten: Op med næbbet. Tænk nu på alle fuglene på taget.

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            gdn55
                            wrote on sidst redigeret af
                            #147

                            Genmab har bevist, at de er gode til at gøre vilde fugle tamme.

                            1 Reply Last reply
                            0
                            • nohopeN Offline
                              nohopeN Offline
                              nohope
                              wrote on sidst redigeret af
                              #148

                              I har fået pip.

                              1 Reply Last reply
                              0
                              • StockBullS Offline
                                StockBullS Offline
                                StockBull
                                wrote on sidst redigeret af
                                #149

                                Pensionist. Vi kan finde nogle svage og stærke perioder for alle aktier så at sammenligne på den måde er helt hen i skoven. Genmab har lige været i en retracement. Så prøv at sammenlign igen næste gang Genmab er i ATH hvor DSV måske er i retracement

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #150

                                  God morgen. 🙂

                                  1 Reply Last reply
                                  0
                                  • Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktør
                                    wrote on sidst redigeret af
                                    #151

                                    Asien: Japanske aktier presset af nye virusbekymringer https://www.proinvestor.com/investornyt/673822/asien-japanske-aktier-presset-af-nye-virusbekymringer

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #152

                                      Just a moment...

                                      favicon

                                      (www.firstwordpharma.com)

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #153

                                        Summary points from expert feedback:

                                        Abecma’s durable responses and one-and-done convenience make it attractive as 4L option
                                        Outpatient therapy is doable for patients not experiencing early side effects, notably fever

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Sukkeralf
                                          wrote on sidst redigeret af
                                          #154

                                          Abecma will slot in before a raft of recently approved MM drugs, including anti-BCMA antibody-drug-conjugate Blenrep
                                          KOL thinks 3L or even 2L use of Abecma, perhaps followed by maintenance with an IMiD or mAb may be the way of the future
                                          Abecma and ciltacabtagene autoleucel are more similar than different so institutions may end up choosing based on costs

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger